marcus evans group news : top news stories from around our events & companies

 The optimal drug delivery system for a peptide can be designed upfront

Many pharmaceutical companies are looking into alternative drug delivery options to drive growth before patents expire or generic drugs enter the market. However, the optimal drug delivery system can be designed upfront, according to Farooq Qureshi Ph.D. MBA, Senior Principal Scientist / Research Leader at Roche.  

A speaker at the upcoming marcus evans Formulation and Drug Delivery Systems for Peptide and Protein Conference, in San Diego, California, December 3-5, 2012, Qureshi said: "The first marketed product should be the one with the optimal delivery system."  

"In the spirit of getting pharmaceutical products to market faster, companies are going ahead with prototypes that are "good enough", and plan to extend the product's lifecycle later on. Although it may slightly inflate costs and time on our end, the optimal delivery system can be designed upfront. So that when we do go to market, we will already have a highly differentiated drug product," Qureshi elaborated.  

"Very often scientists assess whether a novelty in the delivery system is going to give them a real incremental value or just increase the cost/complexity of the drug product presentation, thus excluding suboptimal choices at the onset. Novelty in drug delivery design and performance has to be conceived upfront before they embark on the delivery system to synergize the overall impact on target indications, active pharmaceutical ingredient (API), and overall benefit to patients and payers ."  

When it comes to commercialisation of drugs, pharmaceutical companies have learned through painful ways that there are many obstacles along the road. "To successfully exploit a new delivery system, they have to look at commercialisation opportunities early on, consider safety, manufacturability, device utilisation, and the regulatory landscape. Regulatory agencies may be fragmented in terms of their consistency in expectations from innovators, thereby introducing a complex maze for navigation through each authority. Sometimes convincing these authorities becomes a slow and tedious process of education and mutual acceptance of novelty. However this trend is changing rapidly."

As these hurdles take time and cost money, many ideas get abandoned at the early stages for ones that are simple, straightforward, and commercially viable at a faster pace. But the industry and the scientific community cannot live with a status quo for the long term, Qureshi believes, otherwise novel delivery systems will not be introduced into the market. Imagine the possibilities for overall value creation for the patients and the society.  

"The success stories with some pharma companies confirm that there are many opportunities in this industry, but to help scientists overcome obstacles, an open innovation approach must be supported, thus connecting the innovation dots with molecules, delivery technologies, and clinical benefit. Not all companies can build these capabilities in their own internal network. We must facilitate the implementation of novel delivery systems through an integrated approach in this open innovation platform," Qureshi concluded.  

For more information about the marcus evans Formulation and Drug Delivery Systems for Peptide and Protein Conference, please visit the event website

Related News and Videos
Further reading by division
THG Sports
Large Scale Events
Ken Mcreddie
Ipswich Town FC